Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31328880 | 1.00 | MMP2 (0.39) | MMP2MMP9MMP8MMP13CYP11B1 | |
| SCHEMBL28375120 | 0.83 | MMP2 (0.36) | MMP2MMP9MMP8MMP13CYP11B1 | |
| SCHEMBL21795792 | 0.82 | MMP2 (0.35) | MMP2MMP9MMP8MMP13CYP11B1 | |
| SCHEMBL28176537 | 0.80 | CYP11B1 (0.40) | MMP2MMP9MMP8MMP13CYP11B1 | |
| SCHEMBL29271395 | 0.79 | NFE2L2 (0.40) | MMP2MMP9MMP8MMP13CYP11B1 | |
| SCHEMBL27843286 | 0.79 | ALDH1A1 (0.45) | — | |
| SCHEMBL28825629 | 0.76 | DAO (0.41) | — | |
| SCHEMBL27801839 | 0.75 | CYP11B1 (0.36) | MMP2MMP9MMP8MMP13CYP11B1 | |
| SCHEMBL28745297 | 0.73 | S100A9 (0.31) | — | |
| SCHEMBL20508396 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| CN-116981665-A | Novel compounds | 思瑞万斯公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-111233863-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| CN-108348525-B | Medical application of hydroxyl purine compound | 广东众生睿创生物科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-111233863-A | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-105566324-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-10-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-2398324-B1 | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8486946-B2 | Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2398324-A1 | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010096338-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | MMP2 874/4885MMP9 397/4885MMP8 296/4885 |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | PNP, PDE2A, PDE7A | MMP2 874/4885MMP9 397/4885MMP8 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.